VOYAGER THERAPEUTICS
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.
VOYAGER THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Life Science
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.voyagertherapeutics.com
Total Employee:
101+
Status:
Active
Contact:
857-259-5340
Email Addresses:
[email protected]
Total Funding:
374 M USD
Technology used in webpage:
IPv6 COVID-19 DigiCert SSL Akamai Hosted RapidSSL About Cookies
Similar Organizations
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Neurocrine Biosciences
Neurocrine Biosciences investment in Post-IPO Equity - Voyager Therapeutics
Fidelity
Fidelity investment in Series B - Voyager Therapeutics
Casdin Capital
Casdin Capital investment in Series B - Voyager Therapeutics
Partner Fund Management
Partner Fund Management investment in Series B - Voyager Therapeutics
Wellington Management
Wellington Management investment in Series B - Voyager Therapeutics
Brookside Capital
Brookside Capital investment in Series B - Voyager Therapeutics
Deerfield
Deerfield investment in Series B - Voyager Therapeutics
Genzyme
Genzyme investment in Corporate Round - Voyager Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Series A - Voyager Therapeutics
Key Employee Changes
Official Site Inspections
http://www.voyagertherapeutics.com Semrush global rank: 3.3 M Semrush visits lastest month: 4.27 K
- Host name: 57.252.154.104.bc.googleusercontent.com
- IP address: 104.154.252.57
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Voyager Therapeutics"
Voyager Therapeutics - Defining Neurogenetic Medicine
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological …See details»
About – Overview - Voyager Therapeutics
Voyager’s leaders bring deep expertise in biopharmaceutical development, neurotherapeutics, genetic medicines, strategic management, and organizational culture. The result is a company delivering on its breakthroughs. Patients …See details»
Investors | Voyager Therapeutics Inc.
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological …See details»
About – Leadership - Voyager Therapeutics
Voyager’s leaders bring deep expertise in biopharmaceutical development, neurotherapeutics, genetic medicines, strategic management, and organizational culture. The result is a company delivering on its breakthroughs.See details»
Release Details - ir.voyagertherapeutics.com
Nov 20, 2024 · - Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy …See details»
Voyager Therapeutics, Inc. | LinkedIn
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases.See details»
Voyager Therapeutics, Inc. - MassBio
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been …See details»
Voyager Therapeutics - Crunchbase Company Profile & Funding
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV …See details»
Voyager Enters into License for Next-Generation Capsid, Bringing ...
Sep 5, 2024 · Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties LEXINGTON, Mass. , …See details»
Voyager Therapeutics Announces Pfizer License of Next …
CAMBRIDGE, Mass. October 4, 2022 -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation …See details»
About – Vision, Mission, Strategy - Voyager Therapeutics
Advancing our prioritized CNS pipeline by achieving preclinical and clinical milestones and establishing proof-of-biology and proof-of-concept. Fueling our future by initiating and …See details»
Novartis, Voyager Therapeutics reach license option agreement …
Basel, March 8, 2022 — Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus …See details»
Release Details - Voyager Therapeutics Inc.
CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next …See details»
Voyager Therapeutics Enters Capsid License Agreement and
Jan 2, 2024 · Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACERâ„¢ capsids and other intellectual property for the respective diseases, and Voyager …See details»
Voyager Therapeutics Enters Capsid License Agreement and …
Jan 2, 2024 · Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACERâ„¢ capsids and other intellectual property for the respective diseases, and Voyager …See details»
Science – Publications - Voyager Therapeutics
Voyager Therapeutics, Inc. 75 Hayden Avenue Lexington, MA 02421 857.259.5340See details»
Voyager Therapeutics Reports Robust Preclinical Activity in Tau ...
LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, …See details»
Voyager Reports Third Quarter 2024 Financial and Operating Results
LEXINGTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, …See details»
Voyager Therapeutics - Overview, News & Similar companies
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases.See details»
Release Details - Voyager Therapeutics Inc.
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, …See details»